Shire announces it will expand its orphan drug portfolio and is ready for future M&A discussions.
Shire raised its profit forecast on Friday, Oct. 24, 2014, despite losing a recent deal with AbbVie. The company told Reuters it planned to double sales to $10 billion by 2020, $7 billion of which would come from its existing products and $3 billion from its pipeline. Analysts say Shire’s share price has still been negatively affected, despite the positive outlook.
According to Reuters, Shire CEO Flamming Ornskov told reporters during a call that Shire will focus on rare diseases and related orphan areas, and emphasized its operations have not been affected by AbbVie’s decision to walk away. Moreover, Ornskov told reporters that it still “has significant firepower to do any M&A deals in target areas.”
Had the US Treasury not changed some of the inversion laws, AbbVie would have benefitted from approximately $15-$18 billion in tax savings over the next 15 years, notes GlobalData analyst Aparna Krishnan in a press release. “By acquiring UK-based Shire, AbbVie’s effective tax rate would have dropped 7%, enhancing its earnings by $350 million on a pro forma basis in 2013.”
Sources:
http://www.reuters.com/article/2014/10/24/shire-results-idUSFWN0SJ00X20141024
http://www.reuters.com/article/2014/10/24/shire-brief-idUSL6N0SJ2MK20141024
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.